Infertility Drugs Market Report by Drug Class (Gonadotropin, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Others), Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular), Distribution Channel (Hos

Infertility Drugs Market Report by Drug Class (Gonadotropin, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, and Others), Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), End User (Male, Female), and Region 2024-2032

The global infertility drugs market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032.

Infertility drugs refer to various medications used to treat infertility and enhance the reproductive health of an individual. They are either injected or taken orally. Some commonly used infertility drugs include gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, ovulatory stimulants, dopamine agonists, and tricyclic antidepressants. They work by stimulating ovulation and follicle development of the ovary in women, whereas they help restore testosterone levels and improve the quality of sperm in men to bring about pregnancy. In recent years, infertility drugs have gained traction among couples who are unable to conceive.

Infertility Drugs Market Trends:
Infertility drugs assist in enhancing the chances of pregnancy in couples by restoring the ability of an individual to contribute to conception. As a result, the rising incidences of infertility and miscarriage represents the primary factor driving the market growth. Besides this, several favorable initiatives undertaken by governments of various countries to spread awareness regarding the available treatment options are catalyzing the demand for infertility drugs. Additionally, there has been a significant increase in the prevalence of chronic diseases, such as cancer, obesity, diabetes, thyroid, polycystic ovarian syndrome (PCOS), and menopausal disorders, on account of hectic work schedules, accompanying stress, and lifestyle changes. Along with this, the declining fertility rates due to delayed pregnancies, late marriages, and unhealthy habits, such as excessive consumption of alcohol, drugs, and smoking, are accelerating the product adoption rates. Furthermore, several key players are engaging in research and development (R&D) activities to launch innovative infertility drugs with enhanced efficacy, lower dosage requirements, and fewer side effects. Moreover, the increasing public funding for developing these drugs and faster drug approvals from various regulatory bodies are propelling the market growth. Other factors, including the escalating demand for generic medicines, improving healthcare infrastructure, rising consumer expenditure capacities, rapid urbanization, and technological advancements, are also providing a positive thrust to the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global infertility drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration, distribution channel and end user.

Breakup by Drug Class:

Gonadotropin
Aromatase Inhibitors
Selective Estrogen Receptor Modulators (SERMs)
Biguanides
Others

Breakup by Route of Administration:

Oral
Intravenous
Subcutaneous
Intramuscular

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

Breakup by End User:

Male
Female

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex.

Key Questions Answered in This Report:
How has the global infertility drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global infertility drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global infertility drugs market and who are the key players?
What is the degree of competition in the industry?